Codexis Stock News

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR). RT-qPCR is currently used widely for viral diagnostic tests, including SARS-CoV-2 nucleic acid amplification tests. This enzyme is specifically engineered and optimized for enhanced thermostability and robustness to address known challenges in handling clinical samples.

Key Prominent Players Covered in the Enzymes Market are BASF, Codexis Inc., Amano Enzyme Inc., DSM, Dupont De Nemours & Co., ABF PLC, AB Enzymes, Dyadic International Inc., Advanced Enzyme Technology Ltd., Affymetrix Inc., Bbi Enzymes Ltd., Basf, Codexis Inc., Nagase & Co. Ltd., Life Technologies, Roche Holding Ag., Sanofi S.A. Key Prominent Players Covered in the Enzymes Market are BASF, Codexis Inc., Amano Enzyme Inc., DSM, Dupont De Nemours & Co., ABF PLC, AB Enzymes, Dyadic International Inc., Advanced Enzyme Technology Ltd., Affymetrix Inc., Bbi Enzymes Ltd., Basf, Codexis Inc., Nagase & Co. Ltd., Life Technologies, Roche Holding Ag., Sanofi S.A.

Wall Street brokerages forecast that Codexis, Inc. (NASDAQ:CDXS) will report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Codexis earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.07). Codexis reported earnings of ($0.06) per []

In the last trading session, 1.07 million Codexis Inc. (NASDAQ:CDXS) shares changed hands as the company’s beta touched 1.60. With the company’s per share price at $33.91 changed hands at $2.47 or 7.86% during last session, the market valuation stood at $2.32B. CDXS’s last price was a discount, traded about -23.89% off its 52-week high … Codexis Inc. (NASDAQ: CDXS): The Stock To Invest In Over The Next Few Months Read More »

Shares of Codexis, Inc. (NASDAQ:CDXS) have been given a consensus recommendation of Buy by the eight analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that []

Exchange Traded Concepts LLC increased its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 11.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,799 shares of the biotechnology companys stock after acquiring an additional 13,789 shares during the period. Exchange []

Codexis, Inc. (NASDAQ:CDXS) has earned a consensus rating of Buy from the eight research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have [] The post Codexis, Inc. (NASDAQ:CDXS) Given Average Rating of Buy by Analysts appeared first on ETF Daily News .

Morgan Stanley cut its holdings in Codexis, Inc. (NASDAQ:CDXS) by 5.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 421,186 shares of the biotechnology companys stock after selling 24,119 shares during the period. Morgan Stanley owned 0.65% of Codexis worth $9,544,000 at the end of the [] The post Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Morgan Stanley appeared first on ETF Daily News .

Codexis, Inc. (NASDAQ:CDXS) rose 4% during trading on Friday . The stock traded as high as $38.35 and last traded at $38.02. Approximately 6,144 shares were traded during trading, a decline of 99% from the average daily volume of 854,582 shares. The stock had previously closed at $36.55. CDXS has been the topic of several []

Codexis, Inc. (NASDAQ:CDXS) CEO John J. Nicols sold 35,000 shares of the companys stock in a transaction that occurred on Wednesday, November 10th. The shares were sold at an average price of $40.29, for a total transaction of $1,410,150.00. The sale was disclosed in a legal filing with the SEC, which is available through the []

Zacks Investment Research cut shares of Codexis (NASDAQ:CDXS) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports. According to Zacks, Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts []

Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report

Codexis is leveraging its core technology to create more effective life science tools.